AllDocs -> cancers

NYS NYC 05 Staten Isl 04 Queens 03 Brooklyn 02 Bronx 01 Manhattan 62 Yates * 61 Wyoming * 60 Westchester 59 Wayne * 58 Washington * 57 Warren * 56 Ulster 55 Tompkins * 54 Tioga * 53 Sullivan * 52 Suffolk 51 Steuben * 50 Seneca * 49 Schuyler * 48 Schoharie * 47 Schenectady 46 Saratoga 45 St Lawrence * 44 Rockland 43 Rensselaer * 42 Putnam * 41 Otsego * 40 Oswego * 39 Orleans * 38 Orange 37 Ontario * 36 Onondaga 35 Oneida 34 Niagara 33 Nassau 32 Montgomery * 31 Monroe 30 Madison * 29 Livingston * 28 Lewis * 27 Jefferson * 26 Herkimer * 25 Hamilton * 24 Greene * 23 Genesee * 22 Fulton * 21 Franklin * 20 Essex * 19 Erie 18 Dutchess 17 Delaware * 16 Cortland * 15 Columbia * 14 Clinton * 13 Chenango * ...

H E L P I N G Y O U L E A R N M O R E A B O U T Y O U R H E A L T H Brain Tumors According to the Brain Tumor Society, more than 100,000 Americans will be diagnosed with a brain tumor over the next year. In children and young adults, brain tumors are the second leading cause of cancer death. The cause is unknown, but certain factors can increase its risk, such as exposure to radiation or having an impaired immune system. In rare cases, brain tumors run in families. In adults, roughly 60 percent of all primary brain tumors (originating in the brain ) are malignant astro- cytomas, such as an anaplastic astrocytoma or glioblastoma multiforme. These tumors grow very rapidly and often spread, invading nearby ...

Brain and Other Nervous System Cancer 14 CANCER INCIDENCE AND MORTALITY IN NEW MEXICO, 1970-1996 Major Epidemiologic Features Brain and other nervous system cancers are relatively rare but often lethal. In the U.S., they account for about 1% of all annually diagnosed cancers and 2 to 3% of all yearly cancer deaths. Roughly 90% of nervous system cancers occur inside the skull, mostly within the brain itself. Brain cancers are among the most debilitating and rapidly fatal of all cancers. Consequently, mortality rates often approximate those for incidence. Brain cancer survival has not measurably improved over recent time. Moreover, both incidence and mortality from brain cancer have been slowly increasing in the U.S. since the mid-1960's. These increases have been attributed in large part to improved diagnostic techniques, however, a role for environmental factors cannot ...

S58 NEW DRUGS IN LUNG CANCER Brain metastases (BM) are estimated to occur in 20% to 40% of cancer patients, and two-thirds of them become symptomatic during their lifetime. The brain is consid- ered to be a sanctuary site for chemotherapy. This concept is based on the observation of objective tumor responses at visceral sites, but not in brain sites, in patients who pre- sent with concomitant visceral and BM that have been treated with chemotherapy. This pattern of response was noted also in patients treated with platinum-based c h e m o t h e r a p y. These clinical findings are consistent with pharmacological data that suggest that cisplatin concen- trations are lower in the normal brain compared with oth- er tissues. Medical treatment of BM differs in non-small cell and small cell lung cancer patients. Non-small cell lung cancer (NSCLC) Over the ...

U . S . GOVERNMENT PRINTING OFFICE WASHINGTON : For sale by the Superintendent of Documents, U.S. Government Printing Office Internet: bookstore.gpo.gov Phone: toll free (866) 512–1800; DC area (202) 512–1800 Fax: (202) 512–2250 Mail: Stop SSOP, Washington, DC 20402–0001 76–311PS 2002 RAISING HEALTH AWARENESS THROUGH EXAM- INING BENIGN BRAIN TUMOR CANCER , ALPHA ONE, AND BREAST IMPLANT ISSUES HEARING BEFORE THE SUBCOMMITTEE ON HEALTH OF THE COMMITTEE ON ENERGY AND COMMERCE HOUSE OF REPRESENTATIVES ONE HUNDRED SEVENTH CONGRESS FIRST SESSION NOVEMBER 15, 2001 Serial No. 107–75 Printed for the use of the Committee on Energy and Commerce ( Available via the World Wide Web: http://www.access.gpo.gov/congress/house VerDate 11-MAY-2000 ...

Vol. 52 - No. 23 June 5, 1998 BROOKHAVEN NATIONAL LABORATORY Director’s Corner N ewsday Series Can Change Misconceptions Mammography and Brain Cancer Treatment — New Approaches Under Development at NSLS Last month, about 350 of the more than 2,400 researchers who use BNL ’s National Synchrotron Light Source ( NSLS ) each year flocked to Brookhaven for the NSLS Annual Users Meeting. Stories about the meeting are planned for next week’s Brookhaven Bulletin. This week, the Bulletin takes a look at the research that two teams of NSLS users are pursuing to help improve some cancer treatment and diagnosis. ‘Dramatic Improvement’ in Breast- Cancer Imaging Tomorrow’s mammo- grams could be much more effective at spotting ex- tremely small and elusive ...

Brain Cancer Complementary Therapy: Suggested Supplementation If you have any questions regarding your treatment options, contact your Physician or Oncologist. To review the complete Brain Cancer Complementary Therapy, visit http://www.canceroption.com ImmuneOption 2 scoops, in water or juice, 3 times daily with meals (6 scoops total a day) BETAGlucan CAOP 1 capsule, 3 times daily, take 30 minutes before meals (3 capsules total a day) ImmuneEssential CAOP 3 drops, sublingual for 5 minutes, 7 times daily (Oral - refrigerate bottle) (21 drops total a day; use applicator) or ImmuneEssential CAOP 7 drops, 3 times daily on skin or afflicted areas (Topical – refrigerate bottle) (21 drops total a day; use applicator) FloraPlusOption ½ teaspoon, 1 time a day in pure water (refrigerate bottle) Vita-C Option 3 to ...

brain cancer 2001 SHOSHONE COUNTY BRAIN CANCER SURVEY RESULTS Cluster Analysis Work Group July, 2001 Rationale for Survey The Cancer Data Registry of Idaho (CDRI) received a report of increased brain cancer incidence in an area of Shoshone County, Idaho. The area of focus was defined as a census block group which is located in Kellogg and bounded by I-90, South Division Street, McKinley Avenue, and East Smelterville Loop. There were 3 cases of brain cancer diagnosed among residents of the block group from 1990-2000; only 0-1 case was expected based upon rates in Idaho. Although 3 is a small number of cases, it is significantly more than expected. While the overall rate of brain cancer was not elevated in Shoshone County, or ZIP Code 83837, it was elevated for the small area of Kellogg. An additional two cases resided outside the area of focus, but worked ...

80 18 Cancer of the brain Summary Relative survival after diagnosis of cancer of the brain is poor when compared with other cancers. During 1992–1997, relative survival one year after diagnosis was 42.2% for males and 41.1% for females. The five-year relative survival proportion after diagnosis of brain cancer was 23.8% for both males and females (Table 18.1). Ten-year relative survival was 21.4% for males and 21.9% for females in 1987–1991, the most recent period for which ten- year relative survival data are available (Figure 18.2; Tables 18.2 and 18.3). Relative survival after diagnosis remained fairly consistent between the periods 1982–1986 and 1992–1997, with no statistically significant trends for either males or females. Five-year relative survival was highest for males and females aged less than 40 years. Within this group, relative survival proportions were highest ...

CANCER of the BRAIN and OTHER NERVOUS SYSTEM Pennsylvania Department of Health - Pennsylvania Cancer Incidence and Mortality 1994-1998 - Page 164 While some cases show an autosomal dominant pattern, no genetic factor has been found to influence the overall incidence of primary nervous system tumors. Etiological factors are obscure. Risk Factors FIGURE 19 Average Annual Age-Adjusted Incidence and Mortality Rates* by Sex and Race, Pennsylvania Residents, 1994-1998 None proven to be effective or currently being evaluated. Early Detection *per 100,000 1970 U.S. standard million population. During 1998, there were 814 cases of primary brain and other central nervous system cancers reported to the Pennsylvania Cancer Registry. This was 9.2 percent lower the 896 cases reported for 1997. The average annual (1994-98) age-adjusted incidence rates ...

All-Ireland cancer statistics 1994-96 90 Brain 21. MALIGNANT CANCER OF THE BRAIN (summary) ICD-O.2 C71 ICD-10 C71 ICD-9 191 Figures presented are for primary, malignant tumours. Cancer of the meninges (ICD-10 C70) or of the central nervous system (C72) other than the brain itself are excluded, except where comparison is made with EU figures. Key facts • Average of 315 new cases per year, 1994-96: 148 in females, 200 in males. • Average of 297 deaths per year: 130 in females, 167 in males. • Age-standardised incidence and mortality rates about 50% higher in males than females. • 11th most common site for cancer incidence in males, 15th in females. • 8th most common cause of cancer deaths in females, 9th in males. • Median age at diagnosis 57 years for females and 55 years for males (lower than for cancers ...

CANCER of the BRAIN and OTHER NERVOUS SYSTEM Pennsylvania Department of Health - Pennsylvania Cancer Incidence and Mortality 1992-1996 - Page 164 While some cases show an autosomal dominant pattern, no genetic factor has been found to influence the overall incidence of primary nervous system tumors. Etiological factors are obscure. Risk Factors FIGURE 19 Average Annual Age-Adjusted Incidence and Mortality Rates* by Sex and Race, Pennsylvania Residents, 1992-1996 None proven to be effective or currently being evaluated. Early Detection *per 100,000 1970 U.S. standard million population. During 1996, there were 875 cases of brain and other central nervous system cancers diagnosed among Pennsylvania residents and reported to the Pennsylvania Cancer Registry, the highest annual number recorded between 1987 and 1996. The average annual (1992-96) ...

Mathematical Modeling of Brain Cancer Page 1 Draft for Comment - Sept. 1999 Mathematical Modeling of Brain Cancer to Identify Promising Combination Treatments Background For aggressive brain cancers such as glioblastoma multiforme (gbm), much of the discussion on this web site and others are on clinical trials for new agents. This is largely because the existing arsenal of treatments is so weak. The clinical trials take drugs that seem promising and test them for safety and efficacy. The trials have prevented widespread use of agents that were dangerous, and have led to some improvements in brain tumor treatments. Life has been marginally extended. Newer treatments generally have fewer side effects than older ones for a similar level of effectiveness. However, taken in the broader context of the disease, the pace of progress through the conventional clinical ...

Researchers Use Crippled Poliovirus to Attack Brain Cancer DURHAM, N.C. -- In a daring yet successful experiment to cure deadly brain tumors, researchers have combined the cancer -killing properties of poliovirus together with a harmless genetic coding element from the common cold. The resulting modified virus created a remarkably strong anti- cancer agent that rapidly killed cancer cells in laboratory cell cultures and in animals -- and without causing polio, said Matthias Gromeier, M.D., assistant professor of molecular genetics and microbiology at the Duke Comprehensive Cancer Center. Testing of the new viral agent in humans should begin within two years, he said. In the study, the modified poliovirus rapidly killed cancer cells derived from primary brain tumors as well as cells derived from breast and colon cancer metastases -- all within a matter of four to six hours. In fact, polio is known ...

Experimental Brain Cancer Treatment Suggested lead: Scientists are conducting early research on a new treatment for brain cancer that could yield better results with fewer side effects. Tom Britt has more. Cut 1SOQ: 60 . ( Preview this in a WAV file in 16-bit mono. ) The human brain has a natural defense mechanism called the "blood barrier." It's a gate that allows blood into the brain while keeping poisons in the blood from getting through. Until now, this barrier has meant that patients undergoing treatment for brain cancer usually had a poor prognosis. Dr. John Sampson of Duke University Medical Center says there is an experimental new treatment that puts the cancer fighting toxins directly into the brain - behind the blood barrier. "What we've done is essentially put the drug behind the gate and now the gate works to our benefit, by keeping the drug in the brain ." Sampson says there ...

New Treatment for Brain Cancer Suggested lead: Researchers say they are encouraged by the results of early phase clinical trials of an experimental new treatment for brain cancer . Tom Britt has more. Cut 1SOQ:60 . ( Preview this in a WAV file in 16-bit mono. ) Researchers at the Duke Comprehensive Cancer Center have started testing a new method for killing cancerous brain tumor cells. It's a new class of drugs called "immunotoxins" -- consisting of a bacterial toxin that has been genetically altered and combined with a protein that makes the killer bacteria avoid normal cells and attack only the cancerous cells in the brain . Duke neurosurgeon Dr. John Sampson is the lead investigator in the study, which involves injecting the immunotoxin directly into the brain . "What we're able to do is basically percolate the drug through the brain using this micro-infusion technology." Sampson ...

989 Am J Epidemiol 2003;157:989–997 American Journal of Epidemiology Copyright © 2003 by the Johns Hopkins Bloomberg School of Public Health All rights reserved Vol. 157, No. 11 Printed in U.S.A. DOI: 10.1093/aje/kwg082 Parental Occupational Exposure to Pesticides and Childhood Brain Cancer Edwin van Wijngaarden 1 , Patricia A. Stewart 2 , Andrew F. Olshan 1 , David A. Savitz 1 , and Greta R. Bunin 3 1 Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC. 2 Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD. 3 Children’s Hospital of Philadelphia, Philadelphia, PA. Received for publication October 2, 2002; accepted for publication December 13, 2002. The authors ...

HEMOTHERAPY and/or WBRT have been the gold standards for metastatic brain tumors from SCLC because SCLCs characteristically spread rapidly and result in numerous microscopic brain metasta- ses. 1,9,10,12 Few reports on radiosurgery for metastatic SCLC-induced brain tumors are available. In this retro- spective study, we reviewed the results of GKS alone for the treatment of brain metastases from SCLC compared with the results from NSCLC according to the same treat- ment protocol at a single institute. Clinical Material and Methods Patient Population Three hundred twenty-four patients with metastatic brain tumors from lung cancer were treated at the Chiba Cardiovascular Center between January 1998 and De- cember 2001. Data obtained in patients meeting the fol- lowing five criteria were evaluated retrospectively: 1) no prior brain tumor ...

SPECIMEN Blankshire Cancer Network: Suspected Brain Tumour Referral Form To make a referral, FAX this form to the Urgent Referral Team at the relevant hospital. If you wish to send an accompanying letter, please do so Please corresponding box for which hospital referred to: Hospital A: fax: tel: Hospital C: fax: tel: Hospital E: fax: tel: Hospital B: fax: tel: Hospital D: fax: tel: Hospital F: fax: tel: From: (use practice stamp if available): Address: .. Post code: .. Date of Referral: ./../ GP’s name: . P.C.G. code:.. Tel no: Fax no. .. Patient Details: Name: . Address: . Post code: . Has the patient previously visited this hospital? Y / N Interpreter required? Y / N D.O.B: / ../ Age: Gender: m/ f Tel no (home): Tel no (work): . New NHS No:. ...

Berkshire Priorities Committee Policy Statement 39 Temozolomide for Brain Cancer Date of Issue August 2001 Review Date March 2004 Malignant glioma is the most common form of primary brain cancer in England and Wales (about 3,500 patients each year) but accounts for less than 1% of all cancers. In Berkshire this is approximately 10-12 patients; patients currently receive supportive care with steroids and or anticonvulsants. The National Institute of Clinical Excellence (NICE) reviewed the one RCT available comparing Temozolomide with procarbazine (225 patients); progression free survival at six months was 21% Vs 8%. However, the median survival advantage was six weeks and not deemed statistically significant. The cost effectiveness of Temozolomide was not considered due to the limited clinical effectiveness evidence available. NICE recommends ...

Joanne's Story: Losing Her Partner to Brain Cancer Dr. Ronit Elk: Hello and welcome to the American Cancer Society Cancer Survivors Network®. My name is Dr. Ronit Elk, and I will be your host today. I will be talking one-on- one with women whose partners had cancer , but unfortunately they have passed away. I myself have been a caregiver for three of my very close family members, all of whom died of cancer , and so I am especially pleased to speak to our guests about these very difficult issues and major challenges. We will talk about what it is like to be a caregiver, like what were some of the most difficult challenges and how this affected this relationship. We will also touch on communication, especially the most difficult issue, I think for most people, which is talking about coming to the end of life. I'd ...

Healing Brain & Kidney Cancer , The Gerson Way, by Charlotte Gerson Kenneth Edward Titus – Brain Tumour Kenneth Edward Titus had problems with repeated falls. In June 1982, he went to his Kaiser doctor who, among other tests, carried out a needle biopsy on his brain . This produced a diagnosis of astrocytoma ( brain cancer ), very bad news indeed, which was given to the patient on his birthday, June 25 th . Edward consulted two other doctors for their “second opinions,” but the diagnosis and the prognosis were the same: he would be dead by Christmas. Surgery was offered as a treatment option. However, Edward had a friend who some six months earlier had submitted to surgery for a brain tumour. He had emerged from the surgery reduced to the status of a vegetable, and had died shortly before Edward was given his diagnosis. With this experience fresh in his mind, he refused surgery. ...

Authors: Byron Kuo Timothy Chan Supervisor: Raymond Ng Department of Computer Science University of British Columbia Analyzing Brain and Breast Cancer Sage Libraries One-Page Abstract The purpose of the study is to first attempt to find what gene s characterize brain and breast cancer . Second, we investigate what similarities there are between the seemingly different types of cancer . To accomplish this task, we have used publicly available SAGE libraries of cancerous and normal brain and breast tissues and applied a common statistical method, the two-sample t-test of unequal variance for the analysis. To reduce the impact of sequencing and comparison errors, we have preprocessed the data before applying the t-test. Preprocessing first involves elimination of tags that only have zero and one counts across all the brain and breast SAGE data. To deal ...

C L I N I C A L & H E A L T H A F F A I R S Table 1 Demographics for People with Brain Metastases from Lung Cancer : Olmsted County, Minnesota, 1988–2000 Men Women n=69 n=69 Age at diagnosis 62.6 years 63.4 years Years from diagnosis 0.9 years 0.6 years to brain metastases Stage/Grade Stage III or IV (T3 or T4) 51 (74%) 59 (85%) Grade 3 or 4 61 (88%) 65 (94%) Cell type Small cell 20 (29%) 19 (28%) Large cell 7 (10%) 1 ( 1%) Adenocarcinoma 28 (41%) 28 (41%) Squamous 7 (10%) 11 (16%) Other 7 (10%) 10 (14%) 1988–1990 1991–1993 1994–1996 1997–1999 Figure Cases of Brain Metastasis as a Proportion of Cases of Primary Cancer : Olmsted County, Minnesota, 1988–2000 *Cases diagnosed at autopsy are excluded. ...